Oxford Vaccine
- All
- News
- Videos
-
Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa
A new "high efficacy" malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Oxford Scientists Launch First Human Vaccine Trials For Nipah Virus
Nipah virus is carried by fruit bats and may also be transmitted by contact with infected animals or from person to person via close contact.
-
WHO Recommends Malaria Vaccine Made By Oxford University, Serum Institute
The R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India has been recommended for use by the World Health Organisation (WHO) after meeting required safety, quality and effectiveness standards.
-
"Now We Have Two": WHO Recommends 2nd Malaria Vaccine For Children
The World Health Organization said Monday that its experts had recommended a second malaria vaccine for children, R21/Matrix-M, developed by Britain's Oxford University.
-
Oxford University, Serum Institute Deliver 'High Efficacy' Malaria Vaccine
A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
India Drug Regulator Allows Serum Insititute To Export Its Malaria Vaccine To UK
India's drug regulator has allowed the export of the first produced-in-India vaccine against malaria, developed by scientists at the University of Oxford and manufactured by Serum Institute to the UK.
-
Oxford Scientists To Study Effects Of Covid Variants, Shots In Pregnancy
Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.
-
Oxford Economics Revises India's 2022 GDP Growth Forecast To 7.9%
Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Serum Institute Pledges $66 Million To Oxford University For Research
Vaccine maker Serum Institute of India (SII) has pledged 50 million pounds ($66.2 million) to the University of Oxford for setting up a research campus that would also house the institute behind the AstraZeneca-Oxford COVID-19 shot.
-
Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa
A new "high efficacy" malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
Oxford Scientists Launch First Human Vaccine Trials For Nipah Virus
Nipah virus is carried by fruit bats and may also be transmitted by contact with infected animals or from person to person via close contact.
-
WHO Recommends Malaria Vaccine Made By Oxford University, Serum Institute
The R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India has been recommended for use by the World Health Organisation (WHO) after meeting required safety, quality and effectiveness standards.
-
"Now We Have Two": WHO Recommends 2nd Malaria Vaccine For Children
The World Health Organization said Monday that its experts had recommended a second malaria vaccine for children, R21/Matrix-M, developed by Britain's Oxford University.
-
Oxford University, Serum Institute Deliver 'High Efficacy' Malaria Vaccine
A University of Oxford developed and Serum Institute of India (SII) manufactured and scaled up "high efficacy" malaria vaccine has been licensed for use in Ghana by Africa's Food and Drugs Authority, the university announced here on Thursday.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
India Drug Regulator Allows Serum Insititute To Export Its Malaria Vaccine To UK
India's drug regulator has allowed the export of the first produced-in-India vaccine against malaria, developed by scientists at the University of Oxford and manufactured by Serum Institute to the UK.
-
Oxford Scientists To Study Effects Of Covid Variants, Shots In Pregnancy
Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.
-
Oxford Economics Revises India's 2022 GDP Growth Forecast To 7.9%
Global forecasting firm Oxford Economics on Tuesday revised India's GDP (gross domestic product) growth forecast to 7.9 per cent from earlier 7.8 per cent for the current financial year 2021-22 (FY22), citing more durable recovery and higher Covid-19 vaccination rates.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Serum Institute Pledges $66 Million To Oxford University For Research
Vaccine maker Serum Institute of India (SII) has pledged 50 million pounds ($66.2 million) to the University of Oxford for setting up a research campus that would also house the institute behind the AstraZeneca-Oxford COVID-19 shot.
